Clinical trial · Interventional

Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.

A Randomized, Placebo-Controlled, Masked, Multicenter Phase III Study Of Photodynamic Therapy With Verteporfin For Injection (VFI) For The Treatment Of Multiple Basal Cell Carcinoma

NCT00049959CI-TRIAL-00004575terminatedPhase 3ClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

The purpose of the two studies is to determine whether an experimental therapy using a photoactive drug, verteporfin, in combination with direct light exposure of basal cell carcinoma of the skin can safely eliminate these skin tumors.

Conditions

Conditions (3)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Basal Cell Carcinoma	Basal Cell Carcinoma	ONTOLOGY_EXACT	0.90
Gorlin Syndrome	—	UNRESOLVED	—
Nevoid Basal Cell Carcinoma Syndrome	—	UNRESOLVED	—

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
verteporfin PDT	Drug	—	UNRESOLVED

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years
Maximum age: 90 Years

Show eligibility criteria text

Inclusion Criteria:

* Currently has at least 3 eligible BCC skin tumors that have never been treated
* Is willing to have these tumor sites surgically removed

Exclusion Criteria:

* Has xeroderma pigmentosum
* Has BCC tumors that are the result of prior radiotherapy or immunosuppression due to an organ transplant
* Is immunosuppressed
* Has abnormal liver function
* Is receiving systemic chemotherapy or has received chemotherapy within the last two years

References

Publications (0)

Data not yet available

No reference posted for this study.